Prognostic Factors Analysis and Nomogram Construction of Dual Primary Lung Cancer: A Population Study

Table 1

Demograghic and clinicopathological characteristics of the modeling and validation groups.

Variables	Modeling group (n = 3791)	Validation group (n = 1620)
	No. of patients (%)	No. of patient (%)
Age
<65	959 (25.2)	411 (25.3)
≥65	2832 (74.8)	1209 (74.7)
Gender
Female	2021 (53.3)	873 (53.8)
Male	1770 (46.7)	747 (46.2)
Race
White	3222 (84.9)	1391 (85.8)
Black	385 (10.2)	143 (8.9)
Others	184 (4.9)	86 (5.3)
Histological type
Aden-aden	708 (18.6)	292 (18.1)
Squa-squa	386 (10.1)	192 (11.8)
Squa-aden	176 (4.7)	78 (4.8)
Aden-squa	153 (4.1)	71 (4.4)
BAC-aden	107 (2.8)	40 (2.5)
Others	2261 (59.7)	947 (58.4)
Interval
<6 months	437 (11.5)	180 (11.1)
≥6 months	3354 (88.5)	1440 (88.9)
Primary site
Bilateral	2494 (65.7)	1065 (65.7)
Ipsilateral	1297 (34.3)	555 (34.3)
Grade
I/well	128 (3.4)	52 (3.2)
II/moderate	616 (16.2)	278 (17.2)
III/poor	971 (25.6)	430 (26.6)
IV/undifferentiated	187 (4.9)	67 (4.1)
Others/unknown	1889 (49.9)	793 (48.9)
Stage
IA	646 (17.0)	262 (16.2)
IB	674 (17.8)	324 (20.0)
IIA	95 (2.6)	51 (3.1)
IIB	206 (5.5)	92 (5.6)
IIIA	476 (12.5)	205 (12.7)
IIIB	702 (18.5)	290 (17.9)
IV	992 (26.1)	396 (24.5)
LN metastasis
No/unknown	1990 (52.4)	877 (54.1)
Yes	1801 (47.6)	743 (45.9)
Surgery
Yes-yes	1285 (34.0)	581 (35.8)
Yes-no	1514 (39.9)	616 (38.1)
No-yes	185 (4.8)	78 (4.8)
No-no	807 (21.3)	345 (21.3)
Radiation
Yes-yes	531 (14.1)	214 (13.3)
Yes-no	516 (13.6)	225 (13.8)
No-yes	970 (25.6)	420 (26.0)
No-no	1774 (46.7)	761 (46.9)
Chemotherapy
Yes-yes	520 (13.7)	220 (13.6)
Yes-no	790 (20.8)	359 (22.2)
No-yes	637 (16.9)	278 (17.1)
No-no	1844 (48.6)	762 (47.1)